Fig. 1From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions“Barcelona-Clinic Liver Cancer” (BCLC) classification and treatment of hepatocellular carcinoma according to the 2018 ESMO and EASL Clinical Practical Guidelines. ECOG PS: Eastern Collaborative Oncology Group Performance Status; TACE: transarterial chemoembolizationBack to article page